首页> 外文期刊>Interdisciplinary Sciences: Computational Life Sciences >System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]Isoquinoline Derivative as Anticancerous Drug Candidate Against it
【24h】

System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]Isoquinoline Derivative as Anticancerous Drug Candidate Against it

机译:鉴定鉴定吲哚癌和生物分子相互作用研究的潜在受体的系统生物学方法[2,1-a]异喹啉衍生物作为抗遗传药物候选者

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer is a public health concern which is spreading throughout the world. Different approaches have been employed to combat this disease. System biology approach has been used to understand the molecular mechanisms of drugs targeting cancer cell’s receptor which have opened-up a window to develop effective drugs for it. We have demonstrated biomolecular interaction studies using the rational drug design of indole[2,1-a]isoquinoline derivative as a potent inhibitor against identified cancerous protein PIK3CA —a catalytic sub-unit of PI3K family protein—and compared its affinity with FDA approved drugs for receptors such as dactolisib, idelalisib, and several others such afatinib, avastin, ceritinib and crizotinib, etc.; by docking against potential receptor to set a cutoff value for our screening. Isoquinolines are small alkaloids with a vast variety of substitution depending upon their biogenetic pattern. Isoquinoline derivatives have been reported for their antimalarial, antibacterial, antifungal and anticancerous activities. The results obtained from the present studies conclude that membrane protein is an efficient drug that can be used to target cancer. Moreover, comparative study with ADMET prediction concludes that isoquinoline can be a potent drug for cancer treatment.
机译:癌症是一种在全世界蔓延的公共卫生问题。已经使用不同的方法来打击这种疾病。系统生物学方法已被用来了解靶向癌细胞受体的药物的分子机制,该受体已经开辟了窗户以开发有效的药物。我们已经证明了使用吲哚的合理药物设计的生物分子相互作用研究[2,1-a]异喹啉衍生物作为含有抗癌的癌症蛋白Pik3ca-a催化亚单位的有效抑制剂 - 并将其与FDA批准的药物的亲和力进行了比较对于杜兰菌,伊替洛丽比布等受体,以及其他Amatinib,Avastin,Ceritinib和Crizotinib等;通过对抗潜在的受体来设置筛选的截止值。异喹啉是小型生物碱,取决于它们的生物发生模式。据报道了异喹啉衍生物用于抗疟疾,抗菌,抗真菌和抗癌的活动。从本研究中获得的结果得出结论,膜蛋白是一种可用于靶向癌症的有效药物。此外,对令人预测的比较研究得出结论,异喹啉可以是癌症治疗的有效药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号